

# EFFICACY CARD REFERENCE LIST 2026

1. Sundaram A, Vaughan B, Kost K, Bankole A, Finer L, Singh S, et al. Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth. *Perspect Sex Reprod Health*. 2017;49(1):7-16.
2. Polis CB, Bradley SE, Bankole A, Onda T, Croft T, Singh S. Typical-use contraceptive failure rates in 43 countries with Demographic and Health Survey data: summary of a detailed report. *Contraception*. 2016;94(1):11-7.
3. Trussell J. Contraceptive failure in the United States. *Contraception*. 2011;83(5):397-404.
4. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. *Contraception*. 2008;77(1):10-21.
5. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. *The New England journal of medicine*. 2012;366(21):1998-2007.
6. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. *Eur J Contracept Reprod Health Care*. 2010;15(1):4-16.
7. Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. *Implanon Study Group. Human reproduction*. 1999;14(4):976-81.
8. Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. *Contraception*. 2015;91(4):280-3.
9. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. *Am J Obstet Gynecol*. 2004;190(1):50-4.
10. Said S, Omar K, Koetsawang S, Kiriwat O, Srisatayapan Y, Kazi A, et al. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. *World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Contraception*. 1986;34(3):223-35.
11. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. *Contraception*. 2009;80(1):7-17.
12. Male and Female Sterilisation: Faculty of Sexual & Reproductive Healthcare Clinical Guidance. *Clinical Effectiveness Unit*; 2014 [updated February 2015; cited 2018 23 October]. Available from: <https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-sterilisation-cpd-sep-2014/>.
13. Kovacs GT, Krins AJ. Female sterilisations with Filshie clips: what is the risk failure? A retrospective survey of 30,000 applications. *J Fam Plann Reprod Health Care*. 2002;28(1):34-5.
14. Barone MA, Irsula B, Chen-Mok M, Sokal DC. Effectiveness of vasectomy using cautery. *BMC urology*. 2004;4(1):10.
15. Dinger J, Minh TD, Buttman N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. *Obstet Gynecol*. 2011;117(1):33-40.
16. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. *Obstet Gynecol*. 2002;100(3):585-93.
17. Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. *Cochrane Database Syst Rev*. 2013;4:CD003552.
18. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review: Efficacy and Pregnancy Outcomes. *Contraception*. 1994;50(6 Suppl 1):S 34-52.
19. Steiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. *Obstet Gynecol*. 2003;101(3):539-47.
20. Walsh TL, Freziers RG, Peacock K, Nelson AL, Clark VA, Bernstein L. Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial. *Perspect Sex Reprod Health*. 2003;35(2):79-86.
21. Freziers RG, Walsh TL, Nelson AL, Clark VA, Coulson AH. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. *Fam Plann Perspect*. 1999;31(2):81-7.
22. Schwartz JL, Weiner DH, Lai JJ, Freziers RG, Creinin MD, Archer DF, et al. Contraceptive efficacy, safety, fit, and acceptability of a single-size diaphragm developed with end-user input. *Obstet Gynecol*. 2015;125(4):895-903.
23. Fertility Awareness Methods: Faculty of Sexual & Reproductive Healthcare Statement. *Clinical Effectiveness Unit*; 2015 [updated November 2015; cited 2019 October 22]. Available from: <https://www.fsrh.org/standards-and-guidance/documents/ceuguidancefertilityawarenessmethods/>.
24. Grimes DA, Gallo MF, Grigorieva V, Nanda K, Schulz KF. Fertility awareness-based methods for contraception. *Cochrane Database Syst Rev*. 2004(4):CD004860.
25. Arevalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. *Contraception*. 2002;65(5):333-8.
26. Berglund Scherwitzl E, Lundberg O, Kopp Kallner H, Gemzell Danielsson K, Trussell J, Scherwitzl R. Perfect-use and typical-use Pearl Index of a contraceptive mobile app. *Contraception*. 2017;96(6):420-5.
27. Frank-Herrmann P, Heil J, Gnoth C, Toledo E, Baur S, Pyper C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. *Hum Reprod*. 2007.
28. Berglund Scherwitzl E, Gemzell Danielsson K, Sellberg JA, Scherwitzl R. Fertility awareness-based mobile application for contraception. *Eur J Contracept Reprod Health Care*. 2016;21(3):234-41.
29. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. *Obstet Gynecol*. 2004;103(1):51-6.
30. Cason P, Cwiak C, Edelman A, Kowal D. *Contraceptive technology*. 22nd Ed. Jones & Bartlett Learning; 2023 Sep 26

# EFFICACY CARD REFERENCE LIST 2026 CONT.

34. Graesslin O, Korver T. The contraceptive efficacy of Implanon®: a review of clinical trials and marketing experience. *The European Journal of Contraception & Reproductive Health Care*. 2008 Jan 1;13(sup1):4-12.
34. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S; WHO Study Group on Contraceptive Implants for Women. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. *Hum Reprod*. 2015 Nov;30(11):2527-38. doi: 10.1093/humrep/dev221. Epub 2015 Sep 25. PMID: 26409014.
34. UK medical eligibility criteria for contraceptive use. UKMEC 2025. College of Sexual and Reproductive Healthcare. 2025. Available from: UKMEC\_2025.pdf
35. FSRH Guideline Progestogen-only Implant. College of Sexual and Reproductive Healthcare. 2021 Feb (amended 2023 Jul). Available from: [cosrh.org/Common/Uploaded files/documents/fsrh-guideline-progestogen-only-implants.pdf](https://cosrh.org/Common/Uploaded%20files/documents/fsrh-guideline-progestogen-only-implants.pdf)
36. FSRH Guideline Intrauterine Contraception. College of Sexual and Reproductive Healthcare. 2023 Mar (amended 2025 Jan). Available from: [fsrh-clinical-guideline-intrauterine-contraception-mar-23-amended.pdf](https://cosrh.org/Common/Uploaded%20files/documents/fsrh-clinical-guideline-intrauterine-contraception-mar-23-amended.pdf)
37. FSRH Guideline Combined Hormonal Contraception. College of Sexual and Reproductive Healthcare. 2019 Jul (amended 2023). Available from: [fsrh-guideline-combined-hormonal-contraception-october-2023.pdf](https://cosrh.org/Common/Uploaded%20files/documents/fsrh-guideline-combined-hormonal-contraception-october-2023.pdf)
38. FSRH Guideline Progestogen-only Pills. College of Sexual and Reproductive Healthcare. 2022 Aug (amended 2023 Jul). Available from: <https://www.cosrh.org/Common/Uploaded%20files/documents/fsrh-ceu-clinical-guideline-progestogen-only-pills-aug22-amended-11july-2023-.pdf>
39. teiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. *Obstet Gynecol*. 2003;101(3):539-47.
40. Walsh TL, Frezieres RG, Peacock K, Nelson AL, Clark VA, Bernstein L. Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial. *Perspect Sex Reprod Health*. 2003;35(2):79-86.
41. Frezieres RG, Walsh TL, Nelson AL, Clark VA, Coulson AH. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. *Fam Plann Perspect*. 1999;31(2):81-7.
42. Schwartz JL, Weiner DH, Lai JJ, Frezieres RG, Creinin MD, Archer DF, et al. Contraceptive efficacy, safety, fit, and acceptability of a single-size diaphragm developed with end-user input. *Obstet Gynecol*. 2015;125(4):895-903.
43. Fertility Awareness Methods: Faculty of Sexual & Reproductive Healthcare Statement. Clinical Effectiveness Unit; 2015 [updated November 2015; cited 2019 October 22]. Available from: <https://www.fsrh.org/standards-and-guidance/documents/ceuguidancefertilityawarenessmethods/>.
44. Grimes DA, Gallo MF, Grigorieva V, Nanda K, Schulz KF. Fertility awareness-based methods for contraception. *Cochrane Database Syst Rev*. 2004(4):CD004860.
45. Arevalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. *Contraception*. 2002;65(5):333-8.
46. Berglund Scherwitzl E, Lundberg O, Kopp Kallner H, Gemzell Danielsson K, Trussell J, Scherwitzl R. Perfect-use and typical-use Pearl Index of a contraceptive mobile app. *Contraception*. 2017;96(6):420-5.
47. Frank-Herrmann P, Heil J, Gnoth C, Toledo E, Baur S, Pyper C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. *Hum Reprod*. 2007.
48. Berglund Scherwitzl E, Gemzell Danielsson K, Sellberg JA, Scherwitzl R. Fertility awareness-based mobile application for contraception. *Eur J Contracept Reprod Health Care*. 2016;21(3):234-41.
49. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. *Obstet Gynecol*. 2004;103(1):51-6.
50. Cason P, Cwiak C, Edelman A, Kowal D. *Contraceptive technology*. 22nd Ed. Jones & Bartlett Learning; 2023 Sep 26
51. Graesslin O, Korver T. The contraceptive efficacy of Implanon®: a review of clinical trials and marketing experience. *The European Journal of Contraception & Reproductive Health Care*. 2008 Jan 1;13(sup1):4-12.
52. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S; WHO Study Group on Contraceptive Implants for Women. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. *Hum Reprod*. 2015 Nov;30(11):2527-38. doi: 10.1093/humrep/dev221. Epub 2015 Sep 25. PMID: 26409014.
53. UK medical eligibility criteria for contraceptive use. UKMEC 2025. College of Sexual and Reproductive Healthcare. 2025. Available from: UKMEC\_2025.pdf
54. FSRH Guideline Progestogen-only Implant. College of Sexual and Reproductive Healthcare. 2021 Feb (amended 2023 Jul). Available from: [cosrh.org/Common/Uploaded files/documents/fsrh-guideline-progestogen-only-implants.pdf](https://cosrh.org/Common/Uploaded%20files/documents/fsrh-guideline-progestogen-only-implants.pdf)
55. FSRH Guideline Intrauterine Contraception. College of Sexual and Reproductive Healthcare. 2023 Mar (amended 2025 Jan). Available from: [fsrh-clinical-guideline-intrauterine-contraception-mar-23-amended.pdf](https://cosrh.org/Common/Uploaded%20files/documents/fsrh-clinical-guideline-intrauterine-contraception-mar-23-amended.pdf)
56. FSRH Guideline Combined Hormonal Contraception. College of Sexual and Reproductive Healthcare. 2019 Jul (amended 2023). Available from: [fsrh-guideline-combined-hormonal-contraception-october-2023.pdf](https://cosrh.org/Common/Uploaded%20files/documents/fsrh-guideline-combined-hormonal-contraception-october-2023.pdf)
57. FSRH Guideline Progestogen-only Pills. College of Sexual and Reproductive Healthcare. 2022 Aug (amended 2023 Jul). Available from: <https://www.cosrh.org/Common/Uploaded%20files/documents/fsrh-ceu-clinical-guideline-progestogen-only-pills-aug22-amended-11july-2023-.pdf>